Does the new pill oveporexton ease narcolepsy symptoms?
Yes, in narcolepsy type 1. Across two 12-week trials of 273 people, oveporexton let people stay awake 14.3 to 19.8 minutes longer on a standard wakefulness test, while the placebo groups got slightly worse. Sleepiness scores and cataplexy attacks also fell far more on the drug than on placebo.
Narcolepsy type 1 is much more than feeling tired. It brings overwhelming daytime sleepiness, cataplexy (sudden bouts of muscle weakness), broken sleep at night, sleep paralysis, and vivid dream-like images while falling asleep or waking up. At its root is a missing supply of orexin, a brain chemical that keeps you awake. Oveporexton is a pill taken twice a day that switches on one of orexin’s docking sites in the brain, called orexin receptor 2. It is built to stand in for the signal these patients have lost. An earlier phase 2 trial had already shown it reduced symptoms, and these two phase 3 trials put it to a bigger test.
What the data show
The main measure was the Maintenance of Wakefulness Test. People are placed in conditions that make it easy to doze off and asked to stay awake, and the clock runs for up to 40 minutes. After 12 weeks, the average time people stayed awake rose by 14.3 to 19.8 minutes on oveporexton, depending on the dose and the trial. On placebo, it slipped by 0.4 to 0.8 minutes. For every dose in both trials, there was less than a 1 in 1,000 chance that a gap this large was a fluke.
People also rated their own sleepiness on the Epworth Sleepiness Scale, which runs from 0 to 24. Scores dropped by 9.7 to 11.8 points on the drug, compared with 1.5 to 1.7 points on placebo. Cataplexy improved as well. For the typical (median) person on oveporexton, weekly cataplexy attacks fell by 79.0% to 88.8%, compared with 27.7% to 39.1% on placebo. Both gaps again carried less than a 1 in 1,000 chance of being coincidence.
Dr. Kumar’s Take
Oveporexton goes after the missing signal itself rather than simply pushing the brain toward alertness. One pill moved all three things the trials tracked: how long people could stay awake, how sleepy they felt, and how often cataplexy hit.
The size of the change matters. On a test that tops out at 40 minutes, a gain of 14 to 20 minutes is large, and the placebo groups barely moved. The self-rated sleepiness drop of roughly 10 to 12 points on a 24-point scale lines up with it, so this was not a lab number people failed to feel in daily life. What I want to see next is whether these gains hold well beyond 12 weeks, and whether the side effects below settle down or push people to stop.
How the trials were done
These were two separate randomized, placebo-controlled trials. Randomized means chance decided who got the drug, and placebo-controlled means the comparison group took a dummy pill. First Light enrolled 168 people and split them in a 3:3:2 ratio between oveporexton 1 mg twice daily, 2 mg twice daily, and placebo. Radiant Light enrolled 105 people and split them 2:1 between 2 mg twice daily and placebo. Everyone was 16 to 70 years old and had narcolepsy type 1.
Having two trials matters, because a result that repeats in a second group of patients is much harder to explain away.
Safety, limits, and caveats
Side effects were very common. About 86 to 89 of every 100 people on oveporexton had an adverse event of some kind, compared with 43 to 54 of every 100 on placebo. The two most common were needing to urinate more often and short-lived insomnia, and these occurred in a majority of people taking the drug. Trouble sleeping is not a surprise from a drug built to promote wakefulness.
The trials lasted only 12 weeks, which is too short to judge long-term safety or whether the benefit lasts. They were funded by Takeda Development Center Americas, where many of the authors work. And everyone enrolled had narcolepsy type 1, so the results do not extend to narcolepsy type 2 or to daytime sleepiness from other causes.
Practical Takeaways
- If you have narcolepsy type 1, oveporexton is worth raising with your sleep specialist, since it improved wakefulness, sleepiness, and cataplexy together in two trials.
- Go in expecting side effects, because most people on the drug had more frequent urination and short-lived insomnia, and report them to your doctor rather than stopping on your own.
- The trials ran for 12 weeks, so anyone starting the drug should plan regular check-ins on sleep, bladder symptoms, and whether the benefit is holding.
Related Studies and Research
- FDA approves first narcolepsy drug that targets the cause
- How the brain’s sleep and wake circuits work
- Do ADHD brains fall partly asleep while awake?
- Can a weekly HIV pill replace the daily one?
- A weekly shot for type 2 diabetes that also drops 14% of body weight
FAQs
How do doctors measure sleepiness in narcolepsy?
These trials used two tools that measure different things. The Maintenance of Wakefulness Test is objective: it times how long a person can stay awake under drowsy conditions, from 0 to 40 minutes, and 20 minutes or more is considered normal. The Epworth Sleepiness Scale is a questionnaire where people rate how likely they are to doze off in everyday situations, scored from 0 to 24, with under 10 considered normal. When a drug improves both, it means the change shows up on the clock and in how people feel.
Why did cataplexy attacks drop on placebo too?
The typical person on placebo had 27.7% to 39.1% fewer weekly attacks by week 12, even though the dummy pill had no active drug. Symptoms that people count and report themselves often improve in the placebo group of a trial. This is exactly why a placebo group is essential. The real effect of oveporexton is the gap between the two groups, and here the drug groups saw drops of 79.0% to 88.8%, more than double the placebo figure.
Were teenagers included in the oveporexton trials?
Older teenagers could be. Both trials were open to people aged 16 to 70, so the age range stretched from the late teens to adults well into later life. Nobody younger than 16 was eligible, so these trials say nothing about younger children with narcolepsy.
Bottom Line
In two phase 3 trials of 273 people with narcolepsy type 1, twice-daily oveporexton let people stay awake 14.3 to 19.8 minutes longer on a wakefulness test after 12 weeks, cut sleepiness scores by roughly 10 to 12 points, and reduced weekly cataplexy attacks by 79.0% to 88.8% for the typical patient, all far beyond placebo. The price is frequent side effects, mainly more urination and short-lived insomnia. It is a strong 12-week result for a drug aimed at the missing signal behind the disease.
